Zymeworks (NASDAQ:ZYME) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Zymeworks (NASDAQ:ZYME – Free Report) from a buy rating to a strong-buy rating in a report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Get Our Latest Analysis on ZYME

Zymeworks Price Performance

Shares of NASDAQ:ZYME opened at $18.11 on Friday. The firm has a 50 day moving average of $15.27. Zymeworks has a 12-month low of $9.03 and a 12-month high of $18.49. The firm has a market capitalization of $1.36 billion, a P/E ratio of -18.67 and a beta of 1.51.

Zymeworks (NASDAQ:ZYME – Get Free Report) last posted its earnings results on Tuesday, November 8th. The company reported ($1.14) earnings per share (EPS) for the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%. The firm had revenue of $4.40 million during the quarter.

About Zymeworks

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

See Also